Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Scholand

Infectious Disease Meriden, CT Medical Doctor

NPI 1679500268 CMS profile 76084

435 Lewis Ave, Meriden, CT 06451

Open in the dashboard

General payments

$428,328

629 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Scholand of Meriden, CT is reported in the CMS Open Payments database as having received $428,328 across 629 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59,191 75
2024 General $63,732 83
2023 General $84,561 147
2022 General $82,476 113
2021 General $37,627 50
2020 General $23,008 29
2019 General $77,733 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Scholand
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Stephen Scholand were reported at $59,191. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Stephen Scholand Infectious Disease median Middle half National median
2019 $77,733 $190 $60–$862 $163
2020 $23,008 $124 $32–$606 $114
2021 $37,627 $148 $38–$905 $132
2022 $82,476 $166 $50–$834 $149
2023 $84,561 $171 $57–$787 $160
2024 $63,732 $176 $52–$752 $164
2025 $59,191 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Grifols USA, LLC $365,185 536 payments
  2. Sanofi Pasteur Inc. $48,964 62 payments
  3. Pfizer Inc. $13,293 21 payments
  4. Grifols Shared Services North America, Inc. $583 7 payments
  5. Shionogi Inc $246 2 payments
  6. Paratek Pharmaceuticals, Inc. $56 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $326,716 125 payments
  2. Travel and Lodging $69,182 327 payments
  3. Consulting Fee $21,782 11 payments
  4. Food and Beverage $10,648 166 payments
Products named General payments · program years 2019–2025
  1. HyperRAB $296,041 432 payments
  2. HyperRAB SD $69,727 111 payments
  3. HyperTET SD $67,916 105 payments
  4. HyperTET $35,111 44 payments
  5. FLUZONE HIGH-DOSE Vaccines $18,663 24 payments
  6. FLUZONE HIGH-DOSE Vaccines $8,205 15 payments
  7. TRUMENBA $7,923 13 payments
  8. FLUBLOK QUADRIVALENT $6,889 7 payments
  9. FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE $6,420 6 payments
  10. FLUZONE QUADRIVALENT $4,818 2 payments
  11. Other $14,397 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$29,869

Medicare's payments for the services billed

Medicare patients

177

Average age 75

Services billed

385

85 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 57%
Arthritis 56%
Diabetes 52%
Ischemic heart disease 51%
Heart failure 50%
Depression 47%
Atrial fibrillation 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

629 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record